Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saquinavir SGC Regimens in HIV-1
NCT00002378Phase 3Completed
- Sponsor
- Roche
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of saquinavir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Roche. Primary endpoint: Proportion of patients with plasma HIV-1 RNA < 400 copies/ml at 48 weeks. Status: completed.
02
Drugs
saquinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002378.